News ArticleLaurus Labs Achieves INR 2,206 Crores Revenue in Q2 FY27 with Key Acquisitions to Boost CDMO and Peptide Manufacturing
Company reports 86% growth in CDMO segment and commissions commercial-scale peptide manufacturing, expanding capacities and customer pipeline
Laurus Labs Limited delivered record Q2 FY27 financial results with total revenue of INR 2,206 crores and 34.5% EBITDA margin. The company expanded its CDMO business by 86% in Q2, announced majority acquisitions in Galenvs Sciences and SI & C Resins to strengthen integrated peptide and oligonucleotide manufacturing. It also commissioned commercial-scale peptide manufacturing facilities and maintained growth in affordable medicines portfolio.
Laurus Labs Limited
Earnings Call Transcript
Laurus Labs Limited announced record revenues of INR 2,206 crores for Q2 FY27 propelled by an 86% growth in the CDMO business and strategic acquisitions expanding its peptide and oligonucleotide capabilities.
The company’s small molecule API reactor volume now exceeds 9,000 kiloliters and the peptide synthesis reactor capacity stands at over 16,000 liters, with ongoing expansions in solid- and liquid-phase peptide synthesis.
Laurus Labs acquired a 60% majority stake in Canada-based Galenvs Sciences to enhance its early-stage oligonucleotide and advanced purification expertise, plus a majority stake in Hyderabad-based SI & C Resins to secure peptide resin supply and improve manufacturing competitiveness.
The CDMO segment achieved INR 875 crores in sales for the quarter, up 86%, supported by late-stage programs and commercial API supplies globally, while the affordable medicines portfolio posted revenues of INR 1,302 crores, growing 15% year-on-year.
Operating margins remained robust with a gross margin of approximately 63% and an EBITDA margin of 34.5%, expanding 2.7 percentage points over the previous quarter.
The Laurus Bio segment advanced its fermentation capacity with a new facility expected operational by year-end, supporting longer-term customer relationships and pipeline expansion.
Highlights
- Total Q2 FY27 revenue reaches INR 2,206 crores, a company record.
- CDMO business grows 86% YoY, recording INR 875 crores in Q2 sales.
- Acquires majority stakes in Galenvs Sciences (Canada) and SI & C Resins (India) to bolster peptide and oligonucleotide capabilities.
- Peptide synthesis capacity exceeds 16,000 liters with commercial-scale manufacturing commissioned.
- Affordable medicines segment grows 15% YoY, generating INR 1,302 crores in revenues.
- EBITDA margin expands to 34.5%, improving by 2.7 percentage points versus previous quarter.
Key Data Snapshot
What happened
- Laurus Labs posted record Q2 FY27 total revenues of INR 2,206 crores led by strong CDMO business performance and affordable medicines growth.
- The company commissioned commercial-scale peptide manufacturing capabilities and continues expanding reactor capacities.
- Laurus Labs acquired majority stakes in specialized technology firms Galenvs Sciences and SI & C Resins to expand in oligonucleotide therapies and peptide resin manufacturing, respectively.
Key details
- CDMO sales grew 86% year-over-year to INR 875 crores in Q2 and 77% in first half of FY27 to INR 1,710 crores.
- Affordable medicines revenues grew 15% year-over-year to INR 1,302 crores in Q2 and 13% for the first half of FY27.
- Gross margins maintained around 63% with EBITDA margins improving to 34.5%, an increase of 2.7 percentage points sequentially.
- The peptide manufacturing facility includes solid-phase synthesis capacity over 16,000 liters and plans for further liquid-phase synthesis expansion.
- The company’s acquisition of Galenvs Sciences brings precision magnetic nanoparticle purification and early-stage oligonucleotide capabilities, while SI & C Resins secures critical peptide resins supply.
Strategic context
- Laurus Labs is investing in building integrated scientific capabilities and capacities in advanced therapies including peptides and oligonucleotides.
- The recent acquisitions are designed to provide end-to-end solutions from preclinical development to finished drug products, supporting specialized and complex therapeutic modalities.
- Expansion of manufacturing facilities and technology integration aims to meet growing demand in human health and animal health sectors with global partners.
Highlights
- Total Q2 FY27 revenue reaches INR 2,206 crores, a company record.
- CDMO business grows 86% YoY, recording INR 875 crores in Q2 sales.
- Acquires majority stakes in Galenvs Sciences (Canada) and SI & C Resins (India) to bolster peptide and oligonucleotide capabilities.
- Peptide synthesis capacity exceeds 16,000 liters with commercial-scale manufacturing commissioned.
- Affordable medicines segment grows 15% YoY, generating INR 1,302 crores in revenues.
- EBITDA margin expands to 34.5%, improving by 2.7 percentage points versus previous quarter.
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Source Information
More News on Earnings Call Transcript
View allLatest corporate announcements and market updates in Earnings Call Transcript.
GAIL India Limited Shares Transcript Link for Q2 FY 2026-27 Earnings Call on Unaudited Financial Results
GAIL India Limited has released the transcript link for its earnings conference call held on 30 October 2026, detailing the unaudited financial results for Q2 and the first half of FY 2026-27 ending 30 September 2026.
Read Full Story
Radico Khaitan Delivers Record Q2 FY27 with Over 10 Million IMFL Cases and Rs. 1,746 Crore Revenue
Radico Khaitan Limited reported its strongest second quarter in history for FY27 with over 10 million IMFL cases sold, Rs. 1,746 crore in revenue, and EBITDA of Rs. 356 crore representing a 20.4% margin. Premium and above portfolio volumes grew 36% year-on-year, driving profitability despite input cost volatility.
Read Full Story
ESDS Software Solution Holds Q2 and Half-Year 2026 Earnings Call with Audio Recording Now Accessible
ESDS Software Solution Limited conducted its earnings conference call on November 2, 2026, reviewing financial performance for the quarter and half-year ended September 30, 2026. The event included a discussion by senior management and an interactive question and answer session with investors and analysts.
Read Full Story
